IceCure Medical Advances FDA Review

IceCure Medical(NASDAQ:ICCM) reported second-quarter 2025 results on Aug. 13, 2025, with revenue declining year-over-year to $1.25 million from $1.75 million for the six months ended June 30, 2025. The company highlighted regulatory progress for its ProSense system in breast cancer, a $10 million rights offering to strengthen liquidity, and expanding clinical validation in international markets. Key strategic updates center on the U.S. Food and Drug Administration (FDA) review, financial runway, and global adoption momentum.The de novo marketing authorization request for ProSense is under active review by the FDA, with a comprehensive post-market study protocol submitted as requested. The FDA's requirements include a 400-patient, 30-site post-market commitment, which is shaping operational planning for the company.Successful FDA approval would represent a major inflection point for IceCure Medical, potentially accelerating U.S. commercial adoption and long-term revenue growth.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool